Literature DB >> 29801973

Subsite heterogeneity in the profiles of circulating cytokines in colorectal cancer.

Malgorzata Krzystek-Korpacka1, Marek Zawadzki2, Bartosz Kapturkiewicz3, Paulina Lewandowska4, Iwona Bednarz-Misa4, Sabina Gorska5, Wojciech Witkiewicz6, Andrzej Gamian7.   

Abstract

Colorectal cancers (CRCs) are treated as one entity but are in fact a heterogeneous group of diseases. If not addressed, subsite-associated variability may interfere with mechanism-targeted therapies and accuracy of potential CRC biomarkers. Little is known about the contribution of systemic inflammatory and immune mediators to subsite heterogeneity in CRC. Our purpose was to compare the profiles of key cytokines between right and left colonic and rectal CRCs. Using Luminex xMAP® technology, serum concentrations of eotaxin, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, IFNγ, IP-10, FGF-2, G-CSF, GM-CSF, MCP-1, MIP-1α and β, PDGF-BB, RANTES, TNFα, and VEGF-A were determined in 104 CRC patients. We found the concentrations of IL-12(p70), IL-10, IL-1ra, IL-4, IL-6, IL-7, IL-8, G-CSF and TNFα to be significantly higher in right-sided and GM-CSF in left-sided than rectal CRCs. The concentrations of IFNγ and MIP-1α were significantly higher in right-sided CRCs as compared to cancers of other locations combined. In turn, MIP-1β was higher in rectal CRCs as compared to colon cancers. Taken together, our results show subsite heterogeneity of CRC cancers in terms of systemic inflammatory and immune responses that ought to be taken into account when attempting immunotherapy or developing biomarkers. Additionally, more pronounced TH2 response accompanied by TH1 immunity and more prominent tumor-promoting inflammation in CRC patients with primary tumors originating from right-sided colon may constitute a molecular background of unfavorable prognosis associated with this location.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anatomical subsite heterogeneity; Colorectal cancer; Cytokines; Immune response; Immunotherapy; Inflammation

Mesh:

Substances:

Year:  2018        PMID: 29801973     DOI: 10.1016/j.cyto.2018.05.015

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  13 in total

Review 1.  The dichotomous function of interleukin-9 in cancer diseases.

Authors:  K Gerlach; B Weigmann
Journal:  J Mol Med (Berl)       Date:  2019-08-08       Impact factor: 4.599

2.  TRIM29 is differentially expressed in colorectal cancers of different primary locations and affects survival by regulating tumor immunity based on retrospective study and bioinformatics analysis.

Authors:  Jing Han; Jing Zuo; Xue Zhang; Long Wang; Dan Li; Yudong Wang; Jiayin Liu; Li Feng
Journal:  J Gastrointest Oncol       Date:  2022-06

3.  Interleukin (IL)-7 Signaling in the Tumor Microenvironment.

Authors:  Iwona Bednarz-Misa; Mariusz A Bromke; Małgorzata Krzystek-Korpacka
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  TH9, TH17, and TH22 Cell Subsets and Their Main Cytokine Products in the Pathogenesis of Colorectal Cancer.

Authors:  Guanglin Cui
Journal:  Front Oncol       Date:  2019-10-04       Impact factor: 6.244

5.  Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials.

Authors:  Xia-Hong You; Yu-Huan Jiang; Zhou Fang; Fan Sun; Yao Li; Wei Wang; Zi-Jin Xia; Xiao-Zhong Wang; Hou-Qun Ying
Journal:  ESMO Open       Date:  2020-03

6.  Biphasic Expression of Atypical Chemokine Receptor (ACKR) 2 and ACKR4 in Colorectal Neoplasms in Association with Histopathological Findings.

Authors:  Paulina Lewandowska; Jaroslaw Wierzbicki; Marek Zawadzki; Anil Agrawal; Małgorzata Krzystek-Korpacka
Journal:  Biomolecules       Date:  2020-12-23

7.  Significant and Conflicting Correlation of IL-9 With Prevotella and Bacteroides in Human Colorectal Cancer.

Authors:  Elena Niccolai; Edda Russo; Simone Baldi; Federica Ricci; Giulia Nannini; Matteo Pedone; Francesco Claudio Stingo; Antonio Taddei; Maria Novella Ringressi; Paolo Bechi; Alessio Mengoni; Renato Fani; Giovanni Bacci; Camilla Fagorzi; Carolina Chiellini; Domenico Prisco; Matteo Ramazzotti; Amedeo Amedei
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

Review 8.  Systemic Interleukins' Profile in Early and Advanced Colorectal Cancer.

Authors:  Paulina Czajka-Francuz; Sylwia Cisoń-Jurek; Aleksander Czajka; Maciej Kozaczka; Jerzy Wojnar; Jerzy Chudek; Tomasz Francuz
Journal:  Int J Mol Sci       Date:  2021-12-23       Impact factor: 5.923

Review 9.  Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance.

Authors:  Łukasz Zadka; Damian J Grybowski; Piotr Dzięgiel
Journal:  Cell Oncol (Dordr)       Date:  2020-06-02       Impact factor: 6.730

10.  The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer.

Authors:  Muhammed Üçüncü; Murat Serilmez; Murat Sarı; Süleyman Bademler; Senem Karabulut
Journal:  Biomolecules       Date:  2019-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.